When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Jared R. Adams*, Cara Angelotta, Charles L. Bennett

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

18 Scopus citations
Original languageEnglish (US)
Pages (from-to)2975-2977
Number of pages3
JournalJournal of Clinical Oncology
Issue number19
StatePublished - Jul 1 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this